Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
Alnylam announced it will present new analyses from the Phase 3 HELIOS-B study for vutrisiran in patients with ATTR-CM at the Heart Failure 2026 congress. The presentations highlight a consistent clinical profile and support the use of vutrisiran as a first-line treatment, including in patients with high disease burden or those on concomitant therapies.
Key figures
- Drug Name
- vutrisiran
- Phase Of Trial
- Phase 3
- Knockdown timeframe
- six weeks
- Ttr knockdown percent
- 87%
- Global attr prevalence
- >500,000
- Approved medicines count
- 6
- Vitamin a supplement iu low
- 2500
- Vitamin a supplement iu high
- 3000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.